• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by FibroGen Inc (Amendment)

    2/13/24 5:04:42 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FGEN alert in real time by email
    SC 13G/A 1 tv0921-fibrogeninc.htm SCHEDULE 13G/A fibrogeninc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 9)*

    Name of issuer:  FibroGen Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  31572Q808

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  31572Q808

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    42,258

    7.  SOLE DISPOSITIVE POWER

    6,966,291

    8.  SHARED DISPOSITIVE POWER

    77,858

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,044,149

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.16%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    FibroGen Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    409 Illinois Street
    San Francisco, CA 94158-2509

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    31572Q808

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $FGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FGEN

    DatePrice TargetRatingAnalyst
    8/8/2023$4.00 → $2.00Neutral → Underperform
    BofA Securities
    6/26/2023Buy → Hold
    Stifel
    6/26/2023Buy → Neutral
    BofA Securities
    6/26/2023Outperform → Mkt Perform
    Raymond James
    6/26/2023Outperform → Mkt Perform
    William Blair
    6/2/2023$23.00 → $32.00Hold → Buy
    Stifel
    1/31/2023Mkt Perform → Outperform
    William Blair
    1/26/2023$35.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $FGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

    Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025. About FibroGenFibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadusta

    8/18/25 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for a pivotal Phase 3 trial for roxadustat f

    8/11/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes

    FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burdenCompany intends to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced positive feedback from its Type C meeting with the FDA, supporting the advancement of roxadustat for the treatment of anemia in patients with LR-MDS and high RBC transfusion burden, based on a post-hoc subgroup analysis from the MATTERHORN Phase 3 trial. "We

    8/7/25 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FibroGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded FibroGen from Neutral to Underperform and set a new price target of $2.00 from $4.00 previously

    8/8/23 6:27:35 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen downgraded by Stifel

    Stifel downgraded FibroGen from Buy to Hold

    6/26/23 1:22:02 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen downgraded by BofA Securities

    BofA Securities downgraded FibroGen from Buy to Neutral

    6/26/23 1:16:35 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    7/2/25 4:33:27 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    3/25/25 9:00:05 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schoeneck James A bought $105,040 worth of shares (300,000 units at $0.35) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    3/24/25 9:00:05 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    7/2/25 4:33:27 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ho Maykin

    4 - FIBROGEN INC (0000921299) (Issuer)

    6/6/25 4:20:49 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Edwards Jeffrey L

    4 - FIBROGEN INC (0000921299) (Issuer)

    6/6/25 4:20:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    SEC Filings

    View All

    FibroGen Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FIBROGEN INC (0000921299) (Filer)

    8/18/25 8:45:29 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - FIBROGEN INC (0000921299) (Filer)

    8/13/25 7:53:19 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by FibroGen Inc

    10-Q - FIBROGEN INC (0000921299) (Filer)

    8/11/25 4:10:27 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/14/24 4:52:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 4:01:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 2:33:26 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Financials

    Live finance-specific insights

    View All

    FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for a pivotal Phase 3 trial for roxadustat f

    8/11/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen to Report Second Quarter 2025 Financial Results

    SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call b

    8/4/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

    Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2H 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients

    5/12/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Leadership Updates

    Live Leadership Updates

    View All

    FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

    SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and

    6/9/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Appoints David DeLucia as Chief Financial Officer

    SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili

    12/16/24 8:05:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

    SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him

    3/11/24 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care